BeckCAWilliamsJVAWangJL, et al (2005) Psychotropic medication use in Canada. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie50: 605–613.
2.
BrettJKarangesEADanielsB, et al (2017). Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposure. Australian and New Zealand Journal of Psychiatry51: 990–999.
3.
LuJXuXHuangY, et al (2021) Prevalence of depressive disorders and treatment in China: A cross-sectional epidemiological study. The Lancet Psychiatry8: 981–990.
4.
OhayonMMCauletMPriestRG, et al (1998) Psychotropic medication consumption patterns in the UK general population. Journal of Clinical Epidemiology51: 273–283.
5.
Paulose-RamRSafranMAJonasBSet al (2007) Trends in psychotropic medication use among U.S. adults. Pharmacoepidemiology and Drug Safety16: 560–570.
6.
WestenbergHGSandnerC (2006) Tolerability and safety of fluvoxamine and other antidepressants. International Journal of Clinical Practice60: 482–491.
7.
WongJMotulskyAAbrahamowiczM, et al (2017) Off-label indications for antidepressants in primary care: Descriptive study of prescriptions from an indication based electronic prescribing system. British Medical Journal356: j603.
8.
WuCSShauWYChanHY, et al (2012) Utilization of antidepressants in Taiwan: A nationwide population-based survey from 2000 to 2009. Pharmacoepidemiology and Drug Safety21: 980–988.
9.
ZhangJUngCOLWagnerAK, et al (2019) Medication use during pregnancy in Mainland China: A cross-sectional analysis of a National Health Insurance Database. Clinical Epidemiology11: 1057–1065.
